Blog Archives: Research

Back to Basics: Why Basic Research (and the Fava Bean) are Key to the Cure

Do you hope for new treatments for PD? At the Parkinson’s Disease Foundation, we do. In fact, it’s the reason we exist. But how do we find them? And would you believe me if I told you the fava bean played an important role in the current gold-standard treatment for PD? When we think of finding better PD treatments, we often think of clinical trials — the final stage of research before PD drugs come to market. But there’s a crucial step at the very beginning of the pipeline that makes new drugs possible — basic science. Basic science looks… read more Read More

From Dr. Levy: 2x Your Donation to the Team Ending PD

I’m a scientist and a doctor. Because of funding from the Parkinson’s Disease Foundation, I’m spending my career as a member of the team ending PD. But we need your help. As a young neurologist, PDF’s investment in my two-year fellowship — and its annual investment in my fellow research leaders in the amount of $4.6 million — enabled me and others to join the team fighting PD. But we need your donation to help us meet our goal of ending the disease. When you donate by Thursday, December 31st, your donation will be doubled by the PDF Board of Directors… read more Read More

DBS in Primetime: NatGeo to Air Brain Surgery Live This Sunday

Have you or has a loved one undergone deep brain stimulation surgery for Parkinson’s disease (PD)? Would you undergo the surgery on live television? That’s what is happening on Sunday, October 25 as deep brain stimulation surgery for PD makes its primetime debut on the National Geographic Channel at 9:00 PM ET. Greg Grindley, a 49-year-old father of four living with young onset PD, will undergo the procedure at University Hospitals Case Medical Center in Cleveland, OH, as cameras roll and viewers at home get an up-close look at the brain in real-time.

Et Tu Nilotinib?: Understanding Headlines about an Anti-Cancer Drug for PD

The Society for Neuroscience annual meeting, which took place last week in Chicago, IL, is a place where the latest preliminary data in neuroscience is presented. True to form, there was an interesting abstract presented by Fernando Pagan, M.D. and colleagues from Georgetown University Hospital which suggested a potential treatment for those with Parkinson’s disease (PD). At the heart of the presentation, Dr. Pagan and colleagues reported that in a small trial, an anti-cancer drug called nilotinib was able to reverse both the movement symptoms and cognitive decline of people with PD involved in the study.

Letter from Leadership: My Take on PDF’s Strategic Plan

If you have read the cover article in the Fall 2015 issue of our newsletter, News & Review, you already know that PDF has created a strategic plan to strengthen and accelerate our fight to advance the cure, and care, of Parkinson’s disease. As I enter my 20th anniversary year as chief executive officer of the Parkinson’s Disease Foundation, the new plan is both sobering and exciting.

You Asked & We’re Answering: Fatigue in PD

Why is it important to solve fatigue in PD? First, it is a debilitating symptom experienced by many people with PD; yet it is difficult to diagnose and treat. Perhaps more importantly, it is a symptom that people with PD and care partners told PDF was important when voting in the first Community Choice Research Awards survey. This past October, I was pleased to lead a PDF Conference on Fatigue in PD in Chicago, IL. Because this meeting and subsequent research were inspired by the community, my colleagues and I feel it is important to let you know what happened… read more Read More